Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients
- 677 Downloads
To compare breast cancer subtyping with the three centrally assessed microarray-based assays BluePrint, MammaPrint, and TargetPrint with locally assessed clinical subtyping using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
BluePrint, MammaPrint, and TargetPrint were all performed on fresh tumor samples. Microarray analysis was performed at Agendia Laboratories, blinded for clinical and pathological data. IHC/FISH assessments were performed according to local practice at each institution; estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) assessments were performed on 132 samples, and Ki-67 on 79 samples.
The concordance between BluePrint and IHC/FISH subtyping was 94 % for the Luminal-type, 95 % for the HER2-type, and 94 % for the Basal-type subgroups. The concordance of BluePrint with subtyping using mRNA single gene readout (TargetPrint) was 96 % for the Luminal-type, 97 % for the HER2-type, and 98 % for the Basal-type subgroups. The concordance for substratification into Luminal A and B using MammaPrint and Ki-67 was 68 %. The concordance between TargetPrint and IHC/FISH was 97 % for ER, 80 % for PR, and 95 % for HER2.
The implementation of multigene assays such as TargetPrint, BluePrint, and MammaPrint may improve the clinical management of breast cancer patients. High discordance between Luminal A and B substratification based on MammaPrint versus locally assessed Ki-67 or grade indicates that chemotherapy decisions should not be based on the basis of Ki-67 readout or tumor grade alone. TargetPrint serves as a second opinion for those local pathology settings where high-quality standardization is harder to maintain.
Supported in part by the Associazione Ricerca in Campo Oncologico (ARCO), Cremona, Italy.
- 2.Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, 2011. Ann Oncol. 2011;22:1736–47.PubMedCrossRefGoogle Scholar
- 11.Wesseling J, Cusumano G, Tinterri C, et al. High concordance for microarray based determination of ER, PR and HER2 receptor status and local IHC/FISH assessment worldwide in 827 patients (abstract P5-11-09). Cancer Res. 2011;71(24 Suppl.):543 s.Google Scholar
- 12.Viale G, Bogaerts J, Slaets L, et al. High concordance of protein (by IHC), gene (by FISH; HER2 only) and microarray readout (by TargetPrint) of ER/PR/HER2: results from the MINDACT trial (abstract P1-07-06). Cancer Res. 2011;71(24 Suppl.):190 s.Google Scholar